Nat. Rev. Cardiol. doi: /nrcardio

Slides:



Advertisements
Similar presentations
Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis by David C. Burgess, Michael.
Advertisements

Atrial fibrillation and subcutaneous monitoring : Will it change our daily practice ? Aymeric MENET Lille January 2016.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effect of Intermittent Atrial Tachyarrhythmia.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Remote Monitoring of Implantable Cardioverter-Defibrillators:
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Evidence That D-Dimer Levels Predict Subsequent.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Novel Insight Into the Natural History of Short.
Figure 1 Initial management of a patient with acute heart failure
Figure 2 Survival curves in the elderly vs. younger patients
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Study flow chart.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Figure 1 Flow chart diagram of high-risk group AF patients
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Flow chart of study selection.
Nat. Rev. Cardiol. doi: /nrcardio
Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.
Nat. Rev. Cardiol. doi: /nrcardio
Figure 5 BMI and cardiorespiratory fitness levels
Figure 8 Implanted devices for the management of heart failure
Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 T1 mapping and late gadolinium enhancement (LGE)
Figure 4 BMI and mortality in patients with heart failure
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
José L. Morales et al. JACEP 2017;j.jacep
Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)
Nat. Rev. Cardiol. doi: /nrcardio
Stroke and AF.
Figure 2 Three-year survival rates on the basis of body composition
Figure 7 European Society of Cardiology 2016
Figure 10 Lipomatous hypertrophy of the atrial septum
Figure 4 Prevalence of HFpEF and HFrEF by age
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Health-care system today
David D. Berg et al. JACC 2018;71:
Figure 1 Cardiovascular risk and disease across the life-course
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Decision tree integrating the assessment,
Figure 3 Neural crest cell migration
Figure 2 Global cost of HF per capita in 2012
Figure 5 Examples of biomarker-guided trials
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 U‑shape relationship between exercise dose and risk of atrial fibrillation (AF) Figure 3 | U-shape relationship between exercise dose and risk.
Figure 6 The neurogenic components of angina
Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.
Figure 9 Management of atrial fibrillation
Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Novel markers of increased stroke risk in AF
Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.
Gianluigi Savarese et al. JCHF 2016;4:
Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.
Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.94 Figure 3 Temporal relationship between CIED-detected AHREs and stroke or systemic embolism Figure 3 | Temporal relationship between CIED-detected AHREs and stroke or systemic embolism. Data from the IMPACT trial44. Each horizontal line represents an individual patient, with the time of stroke or systemic embolism indicated by the vertical line. The grey bars represent the duration of cardiac implanted electronic device (CIED) implantation before and after the stroke. Red bars indicate patients with no atrial high-rate episodes (AHREs) before the stroke (9 out of 29 patients had AHREs noted only after the event). No AHREs occurred during the entire monitoring period in 40 patients with thromboembolic events (not shown). Dark grey vertical lines within each horizontal bar represent AHREs, and the height of these thin vertical lines represent the AHRE duration. Oral anticoagulation starts at the green asterisks and stops at the red asterisks. Modified from Martin, D. T. et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur. Heart J. 36 (26), 1660–1668 (2015), with permission from Oxford University Press and the European Society of Cardiology. Modified from Martin, D. T. et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur. Heart J. 36 (26), 1660–1668 (2015), with permission from Oxford University Press and the European Society of Cardiology Freedman, B. et al. (2017) Management of atrial high-rate episodes detected by cardiac implanted electronic devices Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.94